Add Company
Join Now

Genetesis Revenue and Competitors

License our Company Data API

Mason, OH USA

Location

$18.2M

Total Funding

Medical Equip

Industry

Estimated Revenue & Valuation

  • Genetesis's estimated annual revenue is currently $5M per year.(i)
  • Genetesis's estimated revenue per employee is $125,500
  • Genetesis's total funding is $18.2M.

Employee Data

  • Genetesis has 40 Employees.(i)
  • Genetesis grew their employee count by -7% last year.

Genetesis's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
VP ProductReveal Email/Phone
3
ControllerReveal Email/Phone
4
VP PeopleReveal Email/Phone
5
Director Manufacturing and Field ServicesReveal Email/Phone
6
Chief Operations OfficerReveal Email/Phone
7
Co-founder and Chief Technology OfficerReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Engineering ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$254.2M12007%$13.7M$796.9M
#2
$58.8M336N/AN/AN/A
#3
$374.2M1909N/AN/AN/A
#4
$228.6M11428%$45MN/A
#5
$17.3M119-8%$18.2MN/A
#6
$13.9M96-5%N/AN/A
#7
$10.7M7222%N/AN/A
#8
$12.3M85N/AN/AN/A
#9
$1.3M17N/AN/AN/A
#10
$1.5M17N/AN/AN/A
#11
$30.8M114N/AN/AN/A
#12
$173.6M8557%N/AN/A
#13
$36.5M0N/A$43.5MN/A
#14
$1.4M16N/AN/AN/A
#15
$14.1M101-13%$21.5MN/A
#16
$22.4M16014%$35MN/A
#17
$0.3M7N/AN/AN/A
#18
$66.5M224N/AN/AN/A
#19
$2.8M210%$15.8MN/A
#20
$295.8M1457N/AN/AN/A
Add Company

What Is Genetesis?

Genetesis is a commercial-stage medical technology company redefining the way myocardial ischemia and coronary artery disease are clinically diagnosed and triaged by combining our noninvasive biomagnetic imaging technology with proprietary cloud-based web services and machine-learning capabilities. Our initial goal is to be the ultimate rule-out test, in combination with the 12-lead EKG and serial troponins, for clinically significant myocardial ischemia in the acute care setting, We have created a unique web microservices architecture, called the Faraday Analytical Cloud, which combines our easy-to-operate and highly available noninvasive biomagnetic imaging device, called the CardioFlux FAC Magnetocardiograph, with powerful proprietary algorithms that distill data from the device’s measured magnetic field maps into clinically actionable information that integrates seamlessly into clinical and revenue cycle management workflows.

keywords:Medical Devices, Diagnostics, Artificial Intelligence

$18.2M

Total Funding

40

Number of Employees

$5M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Genetesis News

2022-03-22 - Transforming Health-Tech–Startup Challenges into ...

Besides Mekonos, three are in the health-care sector: Genetesis, a magnetic-imaging–based cardiac diagnostics company; Exo, a developer of...

2020-05-11 - Genetesis Raises $9.2M in Series B Financing

Genetesis, Inc., a Mason, Ohio-based cardiac imaging company, raised $9.2M in Series B financing. This included strategic investments from TDK Ventures and an undisclosed Fortune 500 global healthcare company, as well as return investors CincyTech, Ohio Innovation Fund, and Mark Cuban. The com ...

2020-04-21 - TDK Ventures Invests in Biomagnetic Medical Imaging Company Genetesis

Magnetocardiography (MCG) based technology company, Genetesis, is TDK Ventures’ fifth investment from its $50 million venture fund, and first in the healthcare space. Ohio-based Genetesis develops advanced medical imaging solutions for cardiac diagnostics. Genetesis will leverage TDK Corporation ...

2018-06-05 - Biomagnetic Imaging Company Genetesis Raises $7.5M in Series A

Genetesis, a Mason, OH-based medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, closed $7.5M Series A financing. The round was led by CincyTech with participation from existing investors Mark Cuban’s Radical Investments, and ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.8M4011%N/A
#2
$10M408%N/A
#3
$4.6M40-34%N/A
#4
$5.7M4121%N/A
#5
$9.3M430%N/A